Clinical Trial

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Study acronym: NSCLC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-19.
Status change: Not Yet Recruiting → Recruiting 2026-04-07
Trial Details
NCT Number NCT07295821
Lead Sponsor AstraZeneca
Conditions Lung Cancer
Enrollment 60 participants
Start Date 2026-04-01
Primary Completion 2029-05-30 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08